KDR and breast carcinoma: Klement et al. established that orthotopic xenografts of human breast cancer responded significantly to continuous low-dose chemotherapy regimens when used in combination with a second anti-angiogenic drug, i.e., anti-VEGFR-2 antibodies, which led to inhibition of tumour angiogenesis and reduced tumour size [5].